These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 8161332

  • 1. Role of immunoperoxidase staining in serous effusions.
    Sarker AB, Hoshida Y, Nose S.
    Bangladesh Med Res Counc Bull; 1993 Aug; 19(2):33-8. PubMed ID: 8161332
    [Abstract] [Full Text] [Related]

  • 2. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT, Gentile P, Tarectecan A, Fuchs A.
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [Abstract] [Full Text] [Related]

  • 3. [Mesothelial cell. Cytology. Cytochemistry. Immunocytochemistry. Contribution of immunolabelling to the cytodiagnosis of serous effusions with cells of mesothelial aspect].
    Marsan C, Gaulier A, Sabatier P, Garcia R.
    Arch Anat Cytol Pathol; 1993 Oct; 41(5-6):223-8. PubMed ID: 8135583
    [Abstract] [Full Text] [Related]

  • 4. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
    Bassarova AV, Nesland JM, Davidson B.
    Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
    [Abstract] [Full Text] [Related]

  • 5. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
    Hasteh F, Lin GY, Weidner N, Michael CW.
    Cancer Cytopathol; 2010 Apr 25; 118(2):90-6. PubMed ID: 20209622
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [GC12, marker of cells of mesodermal origin. Value and application to cytodiagnosis of serous effusions].
    Daste G, Gioanni J, Lauque D, Kremps M, Mazeau C, Paquis P, Schneider M.
    Arch Anat Cytol Pathol; 1997 Apr 25; 45(4):185-91. PubMed ID: 9406475
    [Abstract] [Full Text] [Related]

  • 8. An immunoperoxidase study of S-100 protein in neoplastic cells in serous effusions. Use as a marker for melanoma.
    Pinto MM.
    Acta Cytol; 1986 Apr 25; 30(3):240-4. PubMed ID: 3521174
    [Abstract] [Full Text] [Related]

  • 9. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
    Davidson B, Berner A, Nesland JM, Risberg B, Kristensen GB, Tropé CG, Bryne M.
    Hum Pathol; 2000 Sep 25; 31(9):1081-7. PubMed ID: 11014575
    [Abstract] [Full Text] [Related]

  • 10. Immunohistochemical localization of prekeratin filaments in benign and malignant cells in effusions. Comparison with intermediate filament distribution by electron microscopy.
    Kahn HJ, Hanna W, Yeger H, Baumal R.
    Am J Pathol; 1982 Nov 25; 109(2):206-14. PubMed ID: 6182803
    [Abstract] [Full Text] [Related]

  • 11. Cytological study of serous effusions with the aid of tumour markers.
    Ray K, Mittal S, Gupta H, Jain M.
    J Indian Med Assoc; 1999 Jan 25; 97(1):11-2, 19. PubMed ID: 10549179
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H.
    Diagn Cytopathol; 2005 Mar 25; 32(3):151-5. PubMed ID: 15690338
    [Abstract] [Full Text] [Related]

  • 14. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology.
    Ko EC, Jhala NC, Shultz JJ, Chhieng DC.
    Am J Clin Pathol; 2001 Nov 25; 116(5):709-15. PubMed ID: 11710688
    [Abstract] [Full Text] [Related]

  • 15. Distribution of silver-stained interphase nucleolar organizer regions as a parameter to distinguish neoplastic from nonneoplastic reactive cells in human effusions.
    Derenzini M, Nardi F, Farabegoli F, Ottinetti A, Roncaroli F, Bussolati G.
    Acta Cytol; 1989 Nov 25; 33(4):491-8. PubMed ID: 2473585
    [Abstract] [Full Text] [Related]

  • 16. Distinguishing benign from malignant pleural effusions by lectin immunocytochemistry.
    Rosen-Levin E, Patil JR, Watson CW, Jagirdar J.
    Acta Cytol; 1989 Nov 25; 33(4):499-504. PubMed ID: 2473586
    [Abstract] [Full Text] [Related]

  • 17. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells.
    Ruitenbeek T, Gouw AS, Poppema S.
    Arch Pathol Lab Med; 1994 Mar 25; 118(3):265-9. PubMed ID: 8135629
    [Abstract] [Full Text] [Related]

  • 18. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
    Afify AM, Stern R, Michael CW.
    Diagn Cytopathol; 2005 Mar 25; 32(3):145-50. PubMed ID: 15690337
    [Abstract] [Full Text] [Related]

  • 19. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
    Shield PW, Koivurinne K.
    Cytopathology; 2008 Aug 25; 19(4):218-23. PubMed ID: 17916095
    [Abstract] [Full Text] [Related]

  • 20. Monoclonal antibodies in the cytodiagnosis of serous effusions.
    al-Nafussi A, Carder PJ.
    Cytopathology; 1990 Aug 25; 1(2):119-28. PubMed ID: 1714782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.